This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

This newsletter contains 100% positive biotech vibes. You may wonder, what has happened to Adam?

A moment to recognize some hopeful news

The 75% slowing of disease progression reported by Uniqure with its Huntington’s disease gene therapy AMT-130 was the kind of stop-reading-and-gasp moment that crystalizes the profound impact these types of one-time treatments can have for patients dealing with rare diseases.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page